Policy & News
Domestic clinical trial approved for bivalent mRNA vaccine against Emmy vaccine
2023-07-03
(Reporter Wang Kara) On 29 June, Amey Vaccines announced that its bivalent mRNA vaccine against the Delta and Omicron BA.5 variant strains of the new coronavirus has been approved by the State Drug Administration and will soon be launched in phase I/II clinical trials in China.
Previously, the vaccine has been approved for Phase III clinical trials in Pakistan, which are now in the finalisation stage. Emmi Vaccine said that after the completion of the relevant clinical trials, the vaccine will apply for registration and marketing in Pakistan.
Early in May this year, the State Council Joint Prevention and Control Mechanism held a press conference, saying that the main prevalent strain of the new coronavirus in China has now changed to the XBB series of mutant strains. on 18 May, the World Health Organisation's advisory panel recommended that the new booster vaccine should aim to be able to generate an antibody response against either the XBB.1.5 or the XBB.1.16 mutant strains.
The bivalent broad-spectrum mRNA vaccine described above by Emmi Vaccine, which was previously tested in two clinical studies conducted in China, showed a favourable safety profile, with results of live virus neutralising antibody testing showing that it was able to induce high levels of neutralising antibodies against the XBB variant of the new coronavirus.
Aiming at Neocoronavirus, Aimé Vaccines is developing several vaccines, including mRNA Neocoronavirus vaccine, second-generation inactivated Neocoronavirus vaccine, and broad-spectrum Neocoronavirus vaccine.
In terms of industrialisation, Aimé Vaccine is also well-prepared. According to the information of Scorch Consulting, the pilot plant of mRNA vaccine of Ammi Vaccine is one of the first batch of production facilities in China to reach the GMP standard, and the mRNA vaccine production plant under construction is designed to have an annual capacity of 400 million doses.
(The above picture shows the clinical trial site in Pakistan, where staff of Aimé Vaccine and local relevant departments are in the midst of intense busyness.)
(Photo in the article provided by Emmi Vaccines for use by China.com)
Source: Sina Finance
Latest News
Promoting Integration with Competitions and Showing Style
The first badminton match of "Kangrun Cup" was successfully held.
Building Elites with Aggressiveness and Winning the Future with Concentration and Effort
Jiangsu Kangrun Biotechnology Co., Ltd. 2023 New Employee Expansion Activities Successfully Conducted
Pre season talk about influenza vaccines: correct cognition without hesitation
Luwang, September 11th (Reporter Guan Xiaohui, Correspondent Li Chengxiu, Ma Jin) Influenza is an acute respiratory infectious disease caused by the influenza virus that poses a threat to human health. It is seasonal (commonly known as the "flu season") and can cause serious complications such as pneumonia, encephalitis, and even death in infants, young children, and the elderly. Therefore, outbreaks of COVID-19 are prone to occur in schools, kindergartens, and elderly care institutions. Although there was a nationwide outbreak of H1N1 influenza A from February to April this year, according to perennial epidemiological data in China, the southern and northern regions generally have a high incidence in winter and spring (November to February of the following year), and the areas south of the Yangtze River can also have a high incidence in summer. Therefore, we are currently in the pre flu season, which is the best time to receive influenza vaccines, especially for infants, young children, primary and secondary school students, the elderly, medical personnel, and entry-exit port staff. However, due to cognitive differences, some parents and vaccination populations have varying degrees of hesitation in vaccination, mostly suspecting the effective protection of the vaccine, followed by anxiety about vaccination safety. For this, let's talk about topics related to influenza vaccines together.
